Hyperbaric oxygen therapy for the treatment of radiation-induced xerostomia: a systematic review

Fox, Nyssa F.; Xiao, Christopher C.; Ak, Sood; Lovelace, Tiffany L.; Nguyen, Shaun A.; Sharma, Anand K.; Day, Terry A.

doi:10.1016/j.oooo.2015.03.007

Cited by 29 publications

(21 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only a few studies analyzed the role of HBOT in post-RT xerostomia, with a limited number of patients included, and were extensively elaborated in a systematic review by Fox et al [55]. In six studies, 227 patients were treated 2 years or more after RT; all but one study were prospective cohort trials and one was a randomized controlled trial, with an average number of HBOT dives between 20 and 43, respectively.…”

Section: Xerostomiamentioning

confidence: 99%

“…not allowing a fair discrimination between the HBOT effect and the placebo effect), lack of appropriate details on RT reported, heterogeneous patient populations (regarding indications for HBOT as the majority was treated for other RT sequelae which could confound the results), and the possibility of publication bias (negative studies may have not been published) limit the strength of the conclusions. Also, no risk assessment was done for cancer recurrence [55]. …”

Section: Xerostomiamentioning

confidence: 99%

See 1 more Smart Citation

Treatment of late sequelae after radiotherapy for head and neck cancer

Strojan

Hutcheson

Eisbruch

et al. 2017

Cancer Treatment Reviews

228

171

View full text Add to dashboard Cite

Radiotherapy (RT) is used to treat approximately 80% of patients with cancer of the head and neck. Despite enormous advances in RT planning and delivery, a significant number of patients will experience radiation-associated toxicities, especially those treated with concurrent systemic agents. Many effective management options are available for acute RT-associated toxicities, but treatment options are much more limited and of variable benefit among patients who develop late sequelae after RT. The adverse impact of developing late tissue damage in irradiated patients may range from bothersome symptoms that negatively affect their quality of life to severe life-threatening complications. In the region of the head and neck, among the most problematic late effects are impaired function of the salivary glands and swallowing apparatus. Other tissues and structures in the region may be at risk, depending mainly on the location of the irradiated tumor relative to the mandible and hearing apparatus. Here, we review the available evidence on the use of different therapeutic strategies to alleviate common late sequelae of RT in head and neck cancer patients, with a focus on the critical assessment of the treatment options for xerostomia, dysphagia, mandibular osteoradionecrosis, trismus, and hearing loss.

show abstract

Section: Xerostomiamentioning

confidence: 99%

Section: Xerostomiamentioning

confidence: 99%

Treatment of late sequelae after radiotherapy for head and neck cancer

Strojan

Hutcheson

Eisbruch

et al. 2017

Cancer Treatment Reviews

228

171

View full text Add to dashboard Cite

show abstract

“…One of the most common sequela of head and neck cancer treatment is radiation‐induced xerostomia, which significantly decreases patients’ quality of life (QOL) by interfering with normal taste, mastication, and deglutition . A number of strategies have been developed to combat xerostomia that include the application of lubricants and saliva substitutes, muscarinic agonists (pilocarpine), amifostine, hyperbaric oxygen treatments, and parotid‐sparing intensity‐modulated radiation therapy (IMRT) . Our group previously established the submandibular gland transfer (SGT) procedure, which involves transferring the submandibular gland (SMG) to the submental space and away from the radiation field …”

Section: Introductionmentioning

confidence: 99%

“…3,4 A number of strategies have been developed to combat xerostomia that include the application of lubricants and saliva substitutes, muscarinic agonists (pilocarpine), amifostine, hyperbaric oxygen treatments, and parotid-sparing intensity-modulated radiation therapy (IMRT). [5][6][7][8][9] Our group previously established the submandibular gland transfer (SGT) procedure, which involves transferring the submandibular gland (SMG) to the submental space and away from the radiation field. 10 The SGT procedure has since been shown to decrease xerostomia using both objective salivary flow tests and qualitative patient-reported xerostomia scores based on the well-validated University of Washington Quality-of-Life Questionnaire (UW-QOL).…”

Section: Introductionmentioning

confidence: 99%

Functional outcomes of the modified submandibular gland transfer procedure

et al. 2019

View full text Add to dashboard Cite

Objectives Treatment for advanced head and neck cancers typically includes surgery followed by radiation therapy (RT). Radiation‐induced xerostomia is a common sequela of these treatments. The modified submandibular gland transfer (M‐SGT) procedure was developed to decrease xerostomia in the treatment of oral cavity cancer by sparing one submandibular gland (SMG) from radiation. This study's objectives were to: 1) elucidate the radiation‐sparing capacity of the M‐SGT, and 2) study the xerostomia‐reducing potential of the M‐SGT based on the University of Washington Quality‐of‐Life Questionnaire (UW‐QOL). Methods Radiation therapy treatment plans were reviewed for all patients treated with surgery and RT who had a M‐SGT at the University of Alberta Hospital during the study period. Outcomes included: 1) radiation dose received by the transferred SMG within the periparotid area compared to the submandibular triangle (ST), and 2) patient‐reported saliva scores on the UW‐QOL compared to historical controls without a gland transfer. Results Twenty‐two patients were included. The mean radiation dose received by the transferred SMG was 29.00 grays (Gy) (standard deviation 14.59 Gy), thus reducing the mean radiation dose to the SMG by a statistically significant 18.34 Gy (confidence interval 95% (13.37, 23.32), P < 0.01) compared to the ST and below the D50 of the SMG (34 Gy). Sixty‐five percent of patients rated their saliva as normal or mildly reduced on the UW‐QOL as compared to 16% of controls (P = 0.01). Conclusion The M‐SGT technique is successful at reducing the radiation dose sustained by the SMG during adjuvant treatment and provides a significant improvement in xerostomia‐related functional outcomes as compared to historical controls not receiving a gland transfer. Level of Evidence 4 Laryngoscope, 130:925–929, 2020

show abstract

“…Gamma-linoleic acid (evening primrose oil, 2000 units daily, ingested over a minimum of 6 weeks) also has been recommended to increase parotid and submandibular gland salivary flow, although its mechanism of action is not clearly understood (Ana, 2002). Hyperbaric oxygen therapyincreases stimulated saliva output, decreased sensation of dry mouth, and hence trend toward improvement in quality of life (Fox, 2015). Artificial salivary gland fabricated based on the principles of tissue engineering (Sood, 2013) and salivary gland transfer also have been implicated as treatment modalities for xerostomia.…”

mentioning

confidence: 99%